• Explore /
  • Poster
  • / Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.

Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.

Abstract Poster

Authors

null

Arvind Katta

Bayer Healthcare Pharmaceuticals, Whippany, NJ

Arvind Katta , Afsaneh Barzi , Brian Thomas Hocum , Sreevalsa Appukkutan , David Cosgrove , Ila Sruti , Junxin Shi , Wei Dai , Gregory A. Patton , Svetlana Babajanyan , Tanios S. Bekaii-Saab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 163)

DOI

10.1200/JCO.2024.42.3_suppl.163

Abstract #

163

Poster Bd #

K11

Abstract Disclosures

Similar Posters

First Author: John H. Strickler

First Author: Yasushi Tsuji

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.

Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.

First Author: Anastasia Danilova

First Author: Ruchit Shah